Introduction {#Sec1}
============

Genetic defects play a major role in the causation of hearing impairment in the human population and many different genes can be involved. More than 130 loci have been identified for nonsyndromic deafness alone, with additional loci involved in syndromic deafness (for review see Nance [@CR36]; Van Camp and Smith ([@CR55]). Although it is expected that many more novel genes are yet to be identified, in many cases the role of those genes already known to be associated with deafness are not fully understood. Mouse models of deafness can be used to study the effects of mutated genes, with the aim of correlating the phenotypic consequences of the mouse mutations to human conditions.

The hush puppy mutant (gene symbol *Hspy*) was identified in an *N*-ethyl-*N*-nitrosourea (ENU) screening programme (Hrabé de Angelis et al. [@CR20]). The phenotype of heterozygous mutant mice was described previously (Pau et al. [@CR39]). Hush puppy heterozygotes were found to have defects in all regions of the ear. In the outer ear the pinna was small, misshapen, and low-set on one or both sides. In the middle ear the stapes were malformed in both ears and incus abnormalities were also found in some cases. Preliminary scanning electron microscopy studies of the inner ear indicated that small regions of the organ of Corti had two rows of outer hair cells instead of the usual three rows. Hearing impairment varied between individual animals, but compound action potential thresholds revealed that all heterozygotes had some increase in thresholds compared to littermate controls. In addition to the ear phenotype, the skull and mandible were shorter in the anteroposterior axis. There was a large amount of variation in the phenotype between individual animals, indicating that there was not full penetrance of the phenotype. For example, penetrance for the pinna defect was estimated at 71%. Genetic mapping of the mutation isolated it to chromosome 8 between markers *D8Mit58* and *D8Mit289*.

The tyrosine kinase receptor fibroblast growth factor receptor 1 (*Fgfr1*) was a very good candidate gene within the identified region because it is known to be expressed in the inner ear, where it is required for development of the auditory sensory epithelium (Pirvola et al. [@CR40]). Stimulation of Fgfr1 by fibroblast growth factors (FGFs) leads to dimerisation and autophosphorylation of the receptor into its active form. The activated receptor interacts with several pathways, including the Ras/MAP kinase pathway and the PLCγ/IP~3~ pathway (for review see Eswarakumar et al. [@CR8]). Previous studies have shown that Fgfr1 is involved in a wide variety of processes, including cell migration during gastrulation (Deng et al. [@CR6]; Yamaguchi et al. [@CR59]), patterning of the anteroposterior axis (Hajihosseini et al. [@CR15]; Partanen et al. [@CR38]), craniofacial morphogenesis (Lee et al. [@CR27]; Riley et al. [@CR46]; Rizzoti and Lovell-Badge [@CR47]), segmentation of the presomitic mesoderm (Wahl et al. [@CR56]), and development of sensory organs (Hebert et al. [@CR18]; Pirvola et al. [@CR40]).

The current study has identified a single-point mutation in the *Fgfr1* gene in the hush puppy mutant. This mutation leads to an amino acid substitution in the kinase domain of the receptor. Study of the homozygote phenotype revealed that the mutation is lethal at approximately embryonic day (E) 8.5, confirming the role of Fgfr1 in early development (Hoch and Soriano [@CR19]). Mutant protein is detected at the cell membrane as normal, but functional studies showed that the mutation causes loss of activation of the Ras/MAP kinase and PLCγ/IP~3~ pathways. The severity of the heterozygote phenotype implies that the mutant protein may be exerting a dominant negative effect, possibly by dimerising with and inhibiting the activity of wild-type protein. In addition, we found evidence of modifiers in the C57BL/6J genome that ameliorate the effect of the *Hspy* mutation. The effects have been analysed using a backcross panel, and a dominant modifier, *Mhspy*, has been localised to the distal end of chromosome 7. *Mhspy* shows different effects depending on whether it is inherited from the mother or the father, consistent with imprinting.

Methods {#Sec2}
=======

Mutant mice {#Sec3}
-----------

The founder mouse (carrying the hush puppy mutation; DEA9) was generated in a large-scale *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis programme (Hrabé de Angelis et al. [@CR20]; Pau et al. [@CR39]). The colony was maintained by heterozygote × wild-type matings on a C3HeB/FeJ background, and heterozygote × heterozygote matings were used to produce the homozygotes for analysis. Age-matched wild-type littermates were used as controls. Once the gene was identified, DNA was extracted from each animal and genotyped using PCR primers 1 and 2 (Table [1](#Tab1){ref-type="table"}), which introduced a *Dde*I restriction site into DNA that contained the mutation. The PCR product was then digested with *Dde*I (100 U/ml) overnight at 37°C, and the resulting fragments were viewed using ethidium bromide agarose gel electrophoresis. Wild-type DNA gave a single band of 208 bp, heterozygote DNA showed as two bands at 184 and 208 bp, and homozygote mutant DNA gave one band at 184 bp.Table 1Primer sequences for genotyping (1 and 2), RT-PCR (3--6), and clone mutagenesis (7--15)PrimerFunctionDirectionSequence (5′--3′)1GenotypingForwardGTGGTCTTTTGGAGTGCTCCTG2GenotypingReverseGCTTGCCAGTGGTGGATCCAA3Fgfr1ForwardCCGGATCTACACACACCAGA4Fgfr1ReverseCCACCAACTGCTTGAACGTA5β-actinForwardATCCATGAAACTACATTCAATTCCAT6β-actinReverseACCGATCCACACAGAGTACTTGCGC7ORFForwardGATCAGTCGACGCCACCATGTGGGGCTGGAAGTGCCTCCTC8ORFReverseGATCAGAATTCTCAGCGCCGTTTGAGTCCACTGTTGGCAAGCTGGGT9E265 KForwardCAGGGCTGCCTGCCAACAAGACAGTGGCCCTGGGC10P457LForwardCAGCGGGACCCCCATGCTGGCTGGAGTCTCCGAATATG11S763 NForwardCATTGTGGCCTTGACCTCCAACCAGGAGTATCTGGACCTG12Flag tagForwardAGGTTGGGGCTGGCCTGGCCTTATCGTCATCGTCTTTGTAGTCAGTGCAGAGAGTGGCTGTG13Flag tagReverseCACAGCCACTCTCTGCACTGACTACAAAGACGATGACGATAAGGCCAGGCCAGCCCCAACCT14HspyForwardGGTCTTTTGGAGTGCTCTTGAGGGAGATCTTCACTCTGGG15HspyReverseCCCAGAGTGAAGATCTCCCTCAAGAGCACTCCAAAAGACC*ORF* open reading frame

Sequencing {#Sec4}
----------

DNA was extracted from wild-type and heterozygous animals. Primers were designed with the aid of Primer3 (Rozen and Skaletsky [@CR48]) to amplify each exon of *Fgfr1*. PCR conditions were as follows: denaturation at 94°C for 5 min; 35 cycles of denaturation at 94°C, followed by annealing at 58°C and extension at 72°C for 30 s each; final extension at 72°C for 5 min. PCR products were then sequenced and the resulting sequences were examined using GAP4 software (Bonfield et al. [@CR5]).

RT-PCR {#Sec5}
------

Whole embryos, including the yolk sac, were dissected at E8.5 and snap-frozen in liquid nitrogen. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The RNA was treated with DNase I (Sigma, UK) to remove any DNA contamination. Half of the purified RNA was reverse-transcribed to cDNA using SuperScript II-reverse transcriptase (Invitrogen, Carlsbad, CA, USA), and the remainder of the RNA was used as a negative control. PCR reactions were carried out with 0.5 μl of cDNA and a final concentration of 500 nM of each primer. PCR and electrophoresis were performed as described above, with the exceptions that the annealing temperature was 57°C and only 30 cycles were used. The primers for *Fgfr1* (Table [1](#Tab1){ref-type="table"}, primers 3 and 4) were designed to encompass the mutation in order to genotype embryos by sequencing the amplified products (as described above). Primers for β-actin (Table [1](#Tab1){ref-type="table"}, primers 5 and 6) were used as an internal control. To quantify the relative change in transcript level between genotypes, band intensities were measured using ImageJ (<http://rsb.info.nih.gov/ij/index.html>). Background levels of luminescence were subtracted from mean band intensities, and *Fgfr1* transcript level was normalised to β-actin transcript.

Clone mutagenesis {#Sec6}
-----------------

The full-length cDNA of murine *Fgfr1* in pBlueScript was obtained from ATCC \[Manassas, VA, USA; pBSmFGFR(L), clone number 63344 (Jin et al. [@CR24])\]. The open reading frame of *mFgfr1* was amplified by PCR from the full-length cDNA using Pfx DNA polymerase (Invitrogen) and primers 7 and 8 (Table [1](#Tab1){ref-type="table"}). After digestion with *Sal*I-*Eco*RI, the PCR product was ligated into pENTR1a (Invitrogen) to generate vector pENTR1a-*mFgfr1*. Comparison of the predicted amino acid sequence to that of *Fgfr1* from wild-type mice with the same genetic background as hush puppy (C3HeB/FeJ) revealed three amino acid differences caused by single nucleotide changes: E265 → K, P457 → L, S763 → N. These differences were corrected in vector pENTR1a-*mFgfr1* using a QuikChange® multisite-directed mutagenesis kit (Stratagene, Agilent Technologies, Santa Clara, CA, USA) and primers 9, 10, and 11, to create vector *Fgfr1*^*WT*^. In this vector, a flag-tag epitope (DYKDDDDK) was inserted after the signal peptide of *mFgfr1* (between amino acids T20 and A21) by site-directed mutagenesis using a QuikChange® II XL site-directed mutagenesis kit (Stratagene) and primers 12 and 13 to generate vector *Fgfr1*^*WT*-*flag*^. The hush puppy mutation W691 → R was added to *Fgfr1*^*WT*-*flag*^ with the QuikChange II XL site-directed mutagenesis kit and primers 14 and 15 to generate vector *Fgfr1*^*Hspy*-*flag*^. Vectors *Fgfr1*^*WT*^, *Fgfr1*^*WT*-*flag*^, and *Fgfr1*^*Hspy*-*flag*^ were recombined into the expression vector pcDNA3.2 using Gateway® LR Clonase Enzyme Mix (Invitrogen).

Cell culture and transfection {#Sec7}
-----------------------------

HEK293 cells were chosen for transient expression studies due to their lack of endogenous Fgfr expression but intact MAP kinase pathway (Li et al. [@CR28]). Cells were maintained in culture with D-MEM:F-12 media supplemented with foetal bovine serum (10%), glutamine (292 μg/ml), penicillin (100 U/ml), and streptomycin (100 μg/ml). Cells were plated into 6- or 24-well plates as required and allowed to adhere for at least 24 h. Transient transfections were performed using Lipofectamine 2000 (Invitrogen).

Immunocytochemistry {#Sec8}
-------------------

HEK293 cells were plated onto 13-mm coverslips coated with poly-[l]{.smallcaps}-lysine (0.01%) and were transfected with 0.5 μg of vector DNA per coverslip as described above. Approximately 24 h after transfection, cells were washed twice with Tris-buffered saline (TBS: 10 mM Trizma base, 150 mM NaCl, pH 7.4) and fixed in methanol and acetone (1:1) for 1 min. Coverslips were washed three times with TBS. Anti-flag antibody conjugated to FITC (10 μg/ml; Sigma) was applied to each coverslip for 1 h at room temperature. Coverslips were washed three times with TBS before being mounted onto glass slides. Cells were then examined under a fluorescence microscope at 488 nm and pictures were taken using AxioVision (release 4.3) software.

Single-cell calcium imaging {#Sec9}
---------------------------

Single-cell calcium imaging (Tovey et al. [@CR52]) was performed on transiently transfected cells to determine if the mutated Fgfr1 receptor could activate the IP~3~ signalling pathway. HEK293 cells were plated onto 22-mm coverslips and transfected with the appropriate vector DNA. Twenty-four hours post transfection, cells were loaded with 2 μM fura-2/AM for 1 h at room temperature. Coverslips were washed in HBS (135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl~2~, 1.5 mM CaCl~2~, 11.6 mM HEPES, 11.5 mM glucose, pH 7.2) for 30 min at room temperature and were then imaged. Cells were excited alternately at 340 and 380 nm for 500 ms each using a monochromator (Cairn, UK). Emitted fluorescence was collected at 510 nm, and images were recorded using a MicroMax 1300Y/HS CCD camera (Princeton Instruments UK, Buckinghamshire, UK). Data was collected and analysed using Metafluor software (Molecular Devices, Sunnyvale, CA, USA). Cells were stimulated with 100 ng/ml FGF1 with 5 μg/ml heparin for 5 min, with data sampled every 5 s. To ensure that cells selected were capable of responding, they were then exposed to 1 mM carbachol (CCh) for 2 min. Fifty cells were selected from each experiment for analysis, and any that failed to respond to CCh were discarded. Each experiment was performed on two independent transfections. Traces were corrected for baseline \[Ca^2+^\]~i~, and the fluorescence ratios (F~340~/F~380~) for individual cells were calculated. These ratios were then calibrated to \[Ca^2+^\]~i~ by referencing a lookup table created using standard Ca^2+^ solutions (Molecular Probes Calcium Calibration Kit with 1 mM MgCl~2~), using the following equation (Grynkiewicz et al. [@CR12]):$$\documentclass[12pt]{minimal}
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Cell stimulation and Western blotting {#Sec10}
-------------------------------------

To determine whether the mutant receptor could activate the Ras/MAP kinase pathway, cells were stimulated with agonist and then lysed. Western blotting was then performed on cell lysates to look for phosphorylation of MAP kinase (MAPK) as an indication of activation of the pathway. HEK293 cells were plated onto 6-well plates and transfected with 1 μg of the required vector DNA per well. Twenty-four hours after transfection, the medium was removed and cells were placed in serum-free medium for 4 h. Cells were washed with HBS before stimulation. Stimulated cells were exposed to 100 ng/ml FGF1 and 5 μg/ml heparin in HBS for 10 min at 37°C. Unstimulated cells had HBS applied during this time. Cells were washed with cold HBS and lysed in 1 ml of 1 × IP buffer (from a protein G immunoprecipitation kit, Sigma). Lysates were incubated on ice for 15--20 min before being centrifuged. The supernatant was removed and stored at --80°C with 10% glycerol until required.

SDS-PAGE was performed using 7.5% acrylamide gels. Proteins were transferred onto nitrocellulose membranes using a mini trans-blotter (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were incubated in blocking solution (10% skimmed milk in TTBS: 50 mM Trizma base, 150 mM NaCl, 0.1% Tween 20, pH 8) for 1--2 h before overnight incubation with the primary antibody at 4°C. Membranes were washed in TTBS before application of secondary antibody (anti-rabbit IgG HRP conjugate, 0.1 μg/ml). After washing with TTBS, membranes were developed using ECL plus Western blotting detection reagent (Amersham, UK) for 5 min. ECL hyperfilm (Amersham) was used to visualise the bands.

In some cases there were low levels of background phosphorylation of MAPK. To compensate for this, levels of phosphorylated MAPK were expressed as a ratio against total MAPK in each lysate, using ImageJ to measure band intensity, as described above.

Antibodies {#Sec11}
----------

For immunocytochemistry, anti-flag M2 monoclonal FITC-conjugated antibodies were obtained from Sigma. Anti-p44/42 MAP kinase and anti-phospho-p44/42 MAP kinase antibodies for Western blotting were acquired from Cell Signaling Technology (Danvers, MA, USA). The anti-rabbit IgG HRP secondary antibodies for Western blotting were from Upstate Biotechnologies (Lake Placid, NY, USA).

Mapping the modifiers {#Sec12}
---------------------

Mice heterozygous for the hush puppy mutation were outcrossed to C57BL/6J. The resulting F1 offspring were genotyped, and then mice carrying the hush puppy mutation were crossed to C3HeB/FeJ to produce the backcross mice used for mapping (*n* = 379 backcross mice). Hush puppy heterozygotes from the backcross generation (*n* = 172) were collected between 5 and 8 weeks of age and used for analysis of the stapes phenotype, skull length, and pinna size except the ones excluded as listed below. An additional 26 heterozygous backcross animals were collected between 7.5 and 8 months of age. These animals were not used in the linkage analysis for the pinna and skull because these tissues continue to grow beyond 8 weeks of age. DNA was prepared from all backcross mice and used for a genome scan using a panel of polymorphic dinucleotide repeat markers covering all 19 autosomes (Table [2](#Tab2){ref-type="table"}). There was no evidence from the distribution of phenotypes for any X-linked modifier.Table 2Markers used for the genome scanMarkerPosition (cM)MarkerPosition (cM)MarkerPosition (cM)*D1Mit429*8.4*D6Mit254*60.55*D13Mit3*8.96*D1Mit415*53.06*D7Mit178*0.5*D13Mit88*21*D1Mit353*90.34*D7Mit230*22.45*D13Mit9*32.44*D2Mit369*27.3*D7Mit66*57.5*D14Mit99*1.51*D2Mit237*28*D7Mit105*63.5*D14Mit260*21.21*D2Mit107*75.6*D7Mit259*72*D14Mit225*44.1*D2Mit200*98.36*D8Mit339*23*D14Mit266*60*D3Mit117*2.35*D8Mit113*52*D15Mit175*5.72*D3Mit339*29.25*D8Mit321*59*D15Mit43*58.01*D3Mit199*56.1*D8Mit280*72*D16Mit165*11.17*D3Mit258*70.3*D9Mit224*17*D16Mit63*30.76*D3Mit19*87.6*D9Mit162*30*D16Mit189*55.2*D4Mit111*21.9*D9Mit214*58.79*D16Mit86*66*D4Mit111*21.9*D10Mit206*4.47*D16Mit106*71*D4Mit58*40.62*D10Mit3*23*D17Mit238*2.22*D4Mit354*71*D10Mit194*29*D17Mit126*21.8*D4Mit234*71*D10Mit180*65.22*D17Mit155*50.71*D4Mit42*81*D11Mit71*0*D18Mit64*2*D5Mit345*1*D11Mit140*25.73*D18Mit37*21*D5Mit391*18.03*D11Mit35*44.74*D18Mit50*41*D5Mit115*40.01*D11Mit99*63.21*D19Mit59*0.5*D5Mit292*80*D12Mit240*3*D19Mit19*26*D6Mit138*2.35*D12Mit69*23.88*D19Mit137*55.7*D6Mit268*15.6*D12Mit14*37*D6Mit323*36.5*D12Nds2*59Positions are given in cM (MGI). All markers were used for each scan, with the exception of *D8Mit321*, which was used only for the scan using stapes sums of 2 or 3 (Fig. [7](#Fig7){ref-type="fig"}a)

Pinnae were removed from each mouse (*n* = 172) shortly after the mouse was culled. Five mice were not included because of pinna damage. Pinnae were flattened under a microscope slide and photographed at a constant magnification. Each pinna was outlined by hand in Adobe Photoshop and the surface area was measured using ImageJ.

After removal of the pinnae, heads were skinned and then placed in 10% neutral buffered formalin for storage prior to dissection of the ossicles. Twenty-seven of the 172 backcross mice had one or both stapes either lost or broken during dissection and could not be used for analysis. An additional 26 backcross mice were collected at 7.5--8 months and processed in the same manner. Stapes were given a score according to how badly affected they were.

Following dissection of the ossicles, the skulls were fixed in ethanol, macerated with potassium hydroxide, stained with Alcian Blue and Alizarin Red, and cleared in glycerol using a standard protocol (Inouye [@CR23]; McLeod [@CR31]).Each skull (*n* = 172) was photographed with a scale. ImageJ was used to measure the length of the skull between the end of the nasal bone and the caudal edge of the interparietal bone. The width of the skull was also measured along the suture at the back of the parietal bone. Nose angle was measured by deviation from the midline of the skull, starting at the base of the nasal bone.

Data analysis {#Sec13}
-------------

Statistical tests were performed using an unpaired two-tailed *t* test, with *P* \< 0.05 considered significant. A regression analysis was carried out to compare stapes score versus pinna size; *P* \< 0.05 was considered significant. Normality, linearity, and homoscedasticity were tested to ensure accuracy of the regression. The Shapiro-Wilks test was used to assess the normality of the distributions of the sums of the stapes scores of mice carrying C57BL/6J DNA from the father and from the mother.

Results {#Sec14}
=======

Hush puppy mutants carry a mutation in the *Fgfr1* gene {#Sec15}
-------------------------------------------------------

DNA was extracted from three wild-type and four heterozygous animals. Primers were designed to amplify each exon of *Fgfr1*. Analysis of the sequence revealed a single-point mutation, T2128A, in exon 15 that was consistently found in all heterozygotes examined (Fig. [1](#Fig1){ref-type="fig"}a). This nucleotide change leads to a substitution in the amino acid sequence such that the tryptophan residue at position 691 is replaced by arginine (W691R). This missense mutation occurs in a region of the Fgfr1 protein that is highly conserved across species orthologues, and also across the family of Fgfrs (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1The hush puppy phenotype is caused by a mutation in *Fgfr1*. **a***Fgfr1* sequence showing the point mutation T2128A (arrow), located in exon 15 of the gene. Sequences from wild-type animals (top), heterozygotes (middle), and homozygotes (bottom) are shown. **b** The point mutation causes the missense mutation W691R in a highly conserved tyrosine kinase motif, subdomain IX (complete domain shown). Numbers shown are the residue number for the equivalent amino acid in each sequence. **c** Development of homozygous embryos is arrested at \~E8.5. Mutant embryos (E8.5) show a characteristic restriction at the embryonic/extra-embryonic boundary (arrow). Heterozygous embryos have no phenotype at this stage. Scale bar = 250 μm. *h* human, *r* rat, *m* mouse, *x* Xenopus, *z* zebrafish, *n* Eastern newt, *d* Drosophila, *ys* yolk sac, *hf* head fold, *s* somites, *A* anterior, *P* posterior

Homozygous hush puppy mutants die at approximately E8.5 {#Sec16}
-------------------------------------------------------

Once the mutated gene had been identified, it was possible to study the effects of the mutation on the protein. Previous studies have shown that overexpression of Fgfr1 leads to anteroposterior patterning defects such as additional digits (Hajihosseini et al. [@CR15]). Conversely, *Fgfr1*-null mice die early in gastrulation, at approximately E8.5 (Deng et al. [@CR6]; Yamaguchi et al. [@CR59]). The homozygote hush puppy phenotype was examined to determine if any of the previously reported phenotypes could be identified. No homozygous animals were present from 56 live births from heterozygote × heterozygote matings, indicating that the embryos died during gestation. Embryos were examined at a range of ages to determine at what stage homozygotes died. No live homozygous animals were detected at E18.5 (0/15), E14.5 (0/18), or E10.5 (0/18), although three homozygous embryos in the process of resorption were found at E10.5. At E8.5 homozygous embryos were detected by sequence analysis, and they were distinguished from littermates by being developmentally retarded, with a restriction at the embryonic/extra-embryonic boundary (Fig. [1](#Fig1){ref-type="fig"}c). In E7.5 embryos the restriction was evident in most cases, although in some it was not as obvious. This phenotype was the same as previously reported in *Fgfr1*-knockout mice (Deng et al. [@CR6]; Yamaguchi et al. [@CR59]), supporting the suggestion that the W691R mutation in Fgfr1 is responsible for the phenotype in hush puppy mice.

The mutation does not prevent transcription of *Fgfr1* {#Sec17}
------------------------------------------------------

The next question was whether the gene was transcribed properly. Messenger RNA was extracted from embryos at E7.5, the stage at which mutants were found to still be viable but were generally identifiable due to their phenotype. It was found that cDNA was present for animals both heterozygous and homozygous for the mutation (Fig. [2](#Fig2){ref-type="fig"}a). *β*-*actin* was used as an internal control to compare levels of expression between samples. The transcript level of *Fgfr1* was normalised relative to *β*-*actin* within each genotype group (Fig. [2](#Fig2){ref-type="fig"}b). The relative cDNA levels of *Fgfr1* were as follows: wild-type, 1.15 ± 0.2 (*n* = 3 animals); heterozygote, 0.49 ± 0.1 (*n* = 7 animals); and homozygotes, 0.23 ± 0.1 (*n* = 8 animals). There was a significant reduction in *Fgfr1* transcript levels compared to wild-type in both heterozygotes (42.6% of wild-type levels, *P* \< 0.05) and homozygotes (20% of wild-type levels, *P* \< 0.001). It has been shown that hypomorphs with reduced transcript levels of only 10% of normal levels die neonatally (Partanen et al. [@CR38]; Pirvola et al. [@CR40]), suggesting that the reduction in transcript levels in hush puppy homozygotes is unlikely to be sufficient to cause death at an early stage (i.e., E8.5), although different genetic backgrounds of the hypomorphs and the hush puppy homozygotes could influence the time of death.Fig. 2Reverse transcription PCR of mRNA (E7.5) from each genotype. The results show that the mutation caused a reduction in the amount of transcript present. **a** PCR products for wild-type (+/+, *n* = 3 animals), heterozygote (*Hspy*/+, *n* = 7 animals), and homozygote (*Hspy/Hspy*, *n* = 8 animals) are shown for both *Fgfr1* and β-actin, the internal control. Control used water in place of cDNA to check for contamination. bp, base pairs. **b** Levels of *Fgfr1* transcript per genotype, normalised to β-actin transcript. *Fgfr1* transcript is significantly reduced compared to wild-type in heterozygotes (*P* \< 0.05) and homozygotes (*P* \< 0.001)

Construct generation {#Sec18}
--------------------

In order to study the mutation in *Fgfr1* further, a construct of the mutated receptor was generated. Three clones were created for study: a clone matching the sequence of *Fgfr1* DNA from wild-type C3HeB/FeJ animals, *Fgfr1*^*WT*^; the wild-type clone with a flag tag, *Fgfr1*^*WT*-*flag*^; and the flag-tagged clone with the hush puppy mutation, *Fgfr1*^*Hspy*-*flag*^. These constructs were transiently expressed in human embryonic kidney (HEK293) cells for further study of the function of the mutated receptor.

Fgfr1^*Hspy*^ protein is localised at the cell membrane {#Sec19}
-------------------------------------------------------

To analyse whether Fgfr1^*Hspy*^ was localised normally, the expression pattern was examined by immunocytochemistry. It was possible that if the mutation caused a disruption in the tertiary structure of the protein, it may not be expressed at the cell membrane due to processing or trafficking errors. HEK293 cells were transiently transfected with either *Fgfr1*^*WT*-*flag*^ or *Fgfr1*^*Hspy*-*flag*^. Immunocytochemistry using an anti-flag FITC-conjugated antibody demonstrated that both the wild-type and the mutated receptor were expressed at the cell membrane (*n* = 3 experiments; Fig. [3](#Fig3){ref-type="fig"}). This indicates that the mutation in *Fgfr1* does not prevent translation of the protein and also does not affect the trafficking of the receptor to the membrane. This in turn indicates that the effect of the mutation is likely to be a functional one.Fig. 3Fgfr1^*Hspy*-*flag*^ is expressed at the cell membrane. Immunocytochemistry using an anti-flag FITC-conjugated antibody showed that the protein is localised to the cell membrane in cells expressing either Fgfr1^*WT*-*flag*^ or Fgfr1^*Hspy*-*flag*^ (*n* = 3 experiments). Scale bar = 20 μm

The mutation prevents mobilisation of intracellular calcium {#Sec20}
-----------------------------------------------------------

Activated Fgfr1 interacts with the phospholipase Cγ (PLCγ) pathway, leading to production of IP~3~, which in turn causes an increase in intracellular calcium ion concentration (\[Ca^2+^\]~i~). Changes in \[Ca^2+^\]~i~ were examined in response to stimulation with FGF1 and heparin (heparin is an accessory molecule that facilitates Fgf binding to Fgfrs) (Kan et al. [@CR25]; Nance [@CR36]; Rapraeger et al. [@CR44]). A subsequent application of CCh (1 mM) was used to ensure cell viability. CCh is an agonist of muscarinic acetylcholine receptors (mAchR), which are endogenously expressed in HEK293 cells. Cells that did not have a CCh response were discounted as it was assumed they lacked a functional Ca^2+^ store or were unhealthy. Nontransfected cells did not respond to FGF1, confirming that there was no endogenous expression of Fgfr1 in the cells (*n* = 194 cells; Fig. [4](#Fig4){ref-type="fig"}a, Table [3](#Tab3){ref-type="table"}). Cells expressing either Fgfr1^*WT*^ or Fgfr1^*WT*-*flag*^ showed an increase in \[Ca^2+^\]~i~ on application of FGF1 and heparin. There was no difference in the number of cells that responded to FGF1 application between cells expressing Fgfr1^*WT*^ (90/194) and Fgfr1^*WT*-*flag*^ (90/189; Table [3](#Tab3){ref-type="table"}). However, there was a small reduction in the amplitude of the response to FGF1 in cells expressing Fgfr1^*WT*-*flag*^ compared to Fgfr1^*WT*^ (134 ± 8.9 and 177.5 ± 12 nM, respectively; Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}b, c). This could be due to lower levels of expression of the construct within cells, or a slightly reduced ability to respond to agonist caused by the presence of the flag tag. Because the introduction of the flag tag did not cause large changes, Fgfr1^*Hspy*-*flag*^ was examined for functional activity. Cells expressing Fgfr1^*Hspy*-*flag*^ showed no rise in \[Ca^2+^\]~i~ when stimulated with FGF1 and heparin (0/376; Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}d). The same cells all responded to CCh (1 mM), confirming that lack of response to FGF1 was not due to cell death. In cells expressing Fgfr1^*WT*^ or Fgfr1^*WT*-*flag*^, the responses to CCh were of significantly reduced amplitude compared to the responses in nontransfected or Fgfr1^*Hspy*-*flag*^-expressing cells. This is most likely due to the cells being unable to refill their intracellular Ca^2+^ stores sufficiently between agonist applications, resulting in a smaller response to the second agonist, i.e., CCh. The mean transfection efficiency of the *Fgfr1*^*WT*^ and *Fgfr1*^*WT*-*flag*^ cells was 47%, and a similar transfection efficiency might be expected with *Fgfr1*^*Hspy*-*flag*^. Counts of transfected cells in immunocytochemistry experiments showed that there were equal levels of transfection between Fgfr1^*WT*-*flag*^ and Fgfr1^*Hspy*-*flag*^ constructs (data not shown). In the Ca^2+^ imaging experiments, of the 376 cells tested with FGF1, \~ 177 would be expected to be expressing Fgfr1^*Hspy*-*flag*^. The lack of response in any cells demonstrated that Fgfr1^*Hspy*-*flag*^ was unable to stimulate the release of intracellular Ca^2+^. This could be due to an inability to activate the PLCγ pathway, which may occur if the receptor's ability to phosphorylate was impaired.Fig. 4Changes in \[Ca^2+^\]~i~ in response to FGF1. Example traces are shown of changes in \[Ca^2+^\]~i~ when FGF1 (100 ng/ml) with heparin (5 mg/ml) is applied to the cells, followed by application of CCh (1 mM, to ensure functional Ca^2+^ stores are present in the cells). **a** There is no response to FGF1 in nontransfected cells (*n* = 194 cells). **b** Cells expressing Fgfr1^*WT*^ give a transient increase in \[Ca^2+^\]~i~ on application of FGF1 (*n* = 194 cells). **c** Addition of the flag tag to the receptor (Fgfr1^*WT*-*flag*^) causes a small reduction in the amplitude of the FGF1 response (*n* = 189 cells). **d** Cells expressing Fgfr1^*Hspy*-*flag*^ gave no increase in \[Ca^2+^\]~i~ in response to FGF1 (*n* = 376 cells)Table 3Percent and amplitude of \[Ca^2+^\]~i~ responses in cells expressing Fgfr1 constructsNo. of cellsFGF1 (100 ng/ml) + heparin (5 μg/ml)Carbachol (1 mM)% respondingChange in \[Ca^2+^\]~i~ (nM)% respondingChange in \[Ca^2+^\]~i~ (nM)Nontransfected19400 ± 0100604 ± 25Fgfr1^*WT*^19446.4178 ± 12^a^10078 ± 7^a,b^Fgfr1^*WT*-*flag*^18947.6134 ± 9^a^10097 ± 11^a,b^Fgfr1^*Hspy*-*flag*^37600 ± 0100561 ± 21^a^There was a significant difference in amplitude of \[Ca^2+^\]~i~ change between Fgfr1^*WT*^ and Fgfr1^*WT*-*flag*^ in response to FGF1 with heparin, but there was no difference between the CCh responses in these cells. CCh amplitudes are given for only the cells that responded to FGF1^b^The response to CCh in cells that gave an FGF1 response was significantly less than in cells that did not respond to FGF1

The MAP kinase pathway is not activated by Fgfr1^*Hspy*-*flag*^ {#Sec21}
---------------------------------------------------------------

Another pathway with which activated Fgfr1 interacts is the MAPK pathway, leading to phosphorylation of MAPK proteins. In order to determine whether the mutated receptor could interact with this pathway, levels of phosphorylated MAPK (phospho-MAPK) under both normal unstimulated and FGF-stimulated conditions were examined by Western blotting (*n* = 5 lysates; Fig. [5](#Fig5){ref-type="fig"}). To compensate for low levels of phospho-MAPK in nontransfected cells, total MAPK was measured in each lysate and phospho-MAPK was then normalised to MAPK levels. It was found that there was a significant difference in levels of phospho-MAPK in nontransfected cells and cells expressing Fgfr1^*WT*-*flag*^ (0.58 ± 0.23 and 2.17 ± 0.48, respectively). The amount of phosphorylation in Fgfr1^*Hspy*-*flag*^-expressing cells was not significantly different than that of nontransfected cells (0.70 ± 0.32). This indicates that the mutated receptor is not capable of activating the MAPK pathway, which could be expected if the mutated receptor had lost its ability to phosphorylate.Fig. 5The hush puppy mutation prevents phosphorylation of MAP kinase. Cells were stimulated with 100 ng/ml FGF1 and 5 mg/ml heparin and then examined for MAPK expression and phosphorylation via Western blotting (*n* = 5 lysates). The top blot shows total MAP kinase in the cell lysates. The bottom blot indicates the amount of MAP kinase that is phosphorylated when stimulated. There was no significant difference between cells expressing Fgfr1^*Hspy*-*flag*^ and nontransfected cells. +, stimulated cells; −, unstimulated cells

Mapping a hush puppy modifier, *Mhspy* {#Sec22}
--------------------------------------

We observed that the hush puppy phenotype is greatly reduced when crossed to a C57BL/6J background, suggesting that there may be modifiers of Fgf signalling in the C57BL/6J genome (Table [4](#Tab4){ref-type="table"}). Accordingly, hush puppy mice were outcrossed to C57BL/6J, then offspring from that cross carrying the *Hspy* mutation were backcrossed to C3HeB/FeJ. The heterozygote offspring from the backcross were examined for stapes defects, pinna size, and skull size. A range of phenotypes was found for the features examined (See Supplementary Figs.) so we analysed mice at the two extremes for each measure. Linkage analysis was carried out comparing those mice with the most normal appearance (the most modified) to those mice with the most affected phenotype (the least modified). There was no evidence from the distribution of phenotypes for any X-linked modifier (data not shown).Table 4Correlation of *Hspy* genotype with ossicle and pinna defects in mice on their original C3HeB/FeJ genetic background and in F1 mice from the outcross of *Hspy/+* mice on a C3HeB/FeJ background to C57BL/6J miceC3HeB/FeJ (original background)F1 mice from *Hspy/+* × C57BL/6J crossWild-typeHush puppy heterozygoteWild-typeHush puppy heterozygoteLeftRightLeftRightLeftRightLeftRightPinna shape0% (0/30)0% (0/30)73.9% (17/23)65.2% (15/23)0% (0/36)0% (0/36)6.5% (2/31)^a^6.5% (2/31)^a^Malleus0% (0/11)0% (0/11)0% (0/13)0% (0/12)0% (0/36)0% (0/36)0% (0/30)0% (0/31)Incus0% (0/36)0% (0/37)21.4% (6/29)14.8% (4/28)0% (0/36)0% (0/35)0% (0/31)0% (0/29)Stapes0% (0/34)0% (0/37)96.4% (27/28)100% (27/27)0% (0/36)0% (0/35)0% (0/31)3.6%^b^ (1/28)Results shown are the percentage of animals with abnormalities, with the number of animals with the defect and number examined in parentheses. Preyer reflex results are not shown; abnormal pinnae often do not flick back when exposed to a click, so the test is not conclusive in these animals. No defects were found in wild-type animals on either background. On the C3HeB/FeJ background, a single heterozygote animal was found to have a unilateral stapes defect, but all other heterozygotes had bilateral stapes malformations^a,b^The single stapes defect observed in the F1 mice was found in an animal with an ipsilateral pinna defect

Stapes were given a score from 1 to 8, depending on their appearance (Fig. [6](#Fig6){ref-type="fig"}, Supplementary Fig. 1) Mice used for linkage analysis were those with a score of 3 or less for left and right ears combined (Fig. [7](#Fig7){ref-type="fig"}a), and mice with a combined score of 10 or more (Fig. [7](#Fig7){ref-type="fig"}b). Only animals with scores available for both ears were used. A notable increase in heterozygosity to over 80% was observed at the distal end of chromosome 7 (markers *D7Mit66*, *D7Mit105*, and *D7Mit259*) in the most modified animals. Conversely, a decrease in heterozygosity was observed in the same location in the least modified animals. The low level of heterozygosity on proximal chromosome 8 corresponds with the location of the *Fgfr1* gene, which was selected for carrying the C3HeB/FeJ-derived *Hspy* mutation.Fig. 6Examples of stapes from the backcross mice, all heterozygotes for the *Fgfr1*^*Hspy*^ mutation. **a** The most modified stapes. Both crura appear relatively normal (score 1). **b** Stapes with thinner than normal posterior crus (score 2). **c** Posterior crus is quite thin in the middle and may be lacking bone in the centre (score 3). **d** Posterior crus lacks bone in the middle but tissue is still present forming a very thin link (score 4). **e** Posterior crus is missing but the stapedial muscle attachment is present at the top right (score 5). **f** Posterior crus is missing, including the stapedial muscle attachment but anterior crus appears normal (score 6). **g** Posterior crus completely missing. Anterior crus is affected and appears thin and often more widely splayed than normal (score 7). **h** Stapes is bony through area between crura. The stapedial artery did not pass through the stapes (score 8). This feature was rarely seen (*n* = 4 ears), and as it appeared to be qualitatively different to the other stapes defects, it was not included in subsequent analyses. **i** Diagram to illustrate the backcross used to map the modifierFig. 7Genome scans using the sum of the stapes defect scores from both left and right ears. **a** Polymorphic microsatellite markers (Table [2](#Tab2){ref-type="table"}) were used on the DNA of animals that had a combined left and right score of 2 or 3. These are therefore the most modified mice from the backcross (*n* = 39 animals). **b** Polymorphic microsatellite markers (Table [2](#Tab2){ref-type="table"}) were used on the DNA of animals that had a combined left and right score of 10 or more. These are therefore the most abnormal (least modified) mice from the backcross (*n* = 36 animals). Mice with a solid bony stapes (Fig. [6](#Fig6){ref-type="fig"}H, score 8 on either side; *n* = 4) were not included in the genome scan

Pinna size was measured at two ages: 5--8 weeks and 7.5--8 months (Supplementary Figs. 2 and 3). The animals used for linkage analysis were those with a combined surface area of both pinnae of 80 units or more (the most modified; Supplementary Fig. 4A) and those with a combined surface area of 60 units or less (the least modified; Supplementary Fig. 4B) from the younger age group. As for the stapes abnormalities, an increase of heterozygosity in the most modified animals and a decrease of heterozygosity in the least modified animals was observed at the distal end of chromosome 7.

To determine if the pinna and stapes defects correlated, a regression analysis was carried out, treating left and right sides separately to ensure independence. A significant negative correlation was observed for both sides (Supplementary Fig. 5; left ear: *r* = -0.665, *n* = 181, *P* \< 2.2 × 10^−16^; right ear: r = -0.617, *n* = 182, *P* \< 2.2 × 10^−16^).

Distal chromosome 7 is subject to imprinting, so we asked whether the putative C57BL/6J-derived modifier might be among the imprinted loci by looking for any skew in the degree of modification of the stapes or pinna phenotype associated with inheriting the modifier from the mother or from the father. We replotted the numbers of mice in each category for the stapes defect and for pinna size according to whether the most distal chromosome 7 marker (*D7Mit259*) from the C57BL/6J parent was inherited from the maternal or the paternal line. For the pinna size, there was no evidence of any difference in distribution (data not shown). However, for the stapes defect, there was a marked skew in the distribution toward the more modified (least abnormal) end of the distribution when the C57BL/6J marker was inherited from the paternal line, but there was no skew when it was inherited from the mother (Fig. [8](#Fig8){ref-type="fig"}). This skew suggests that there may be imprinting of the modifier. For example, the allele derived from the maternal line might be inactivated by imprinting while the allele derived from the paternal line may show no imprinting and hence may be active in compensating in some way for the *Hspy* mutation.Fig. 8The distribution of the sum of the stapes scores for mice carrying distal chromosome 7 C57BL/6J DNA (marker *D7Mit259*) from their father (violet) and for mice carrying distal chromosome 7 C57BL/6J DNA from their mother (maroon). There is a noticeable bias toward the more modified end (scores 2--4) for those mice from a heterozygote father (Shapiro-Wilks test score for mice from a heterozygote father: 6.85 × 10^−7^; score for mice from a heterozygote mother: 0.0501)

The ratio of the skull length (nasal bone to interparietal bone) to the skull width (measured along the suture of the parietal bone) was used to determine which animals had been most modified (length:width ratio \>2.08) and least modified (length:width ratio \<2) (Supplementary Fig. 6A, B). DNA from these animals was used for linkage analysis (Supplementary Figs. 7 and 8). In addition, a small proportion of mice had a marked bend in their nose (measured by deviation from the midline of the skull starting at the base of the nasal bone), and linkage analysis was carried out on those with a bend of greater than 10° (deemed least modified) and those with a bend of less than 2° (most modified; Supplementary Figs. 6C, D and 9). However, there were no obvious peaks in the genome scans for skull length:width ratio or degree of nasal bend.

Discussion {#Sec23}
==========

In this study we have detected a missense mutation in the tyrosine kinase domain of *Fgfr1* leading to a tryptophan-to-arginine substitution in the hush puppy mouse mutant. Embryos that were homozygous for the *Fgfr1*^*Hspy*^ mutation died at gastrulation and demonstrated the same characteristics as *Fgfr1*-knockout embryos (Deng et al. [@CR6]) in that they die at the same time point, with a restriction at the embryonic/extra-embryonic boundary. The mutated gene was transcribed, although at a lower level than in the wild type, and the protein was correctly processed and trafficked to the cell plasma membrane. The functional effect of the mutation on the receptor was such that the receptor could not activate at least two of its downstream pathways, the Ras/MAP kinase pathway and the PLCγ/IP~3~ pathway. In effect, the mutation caused a loss of function of the receptor. There are several possible explanations of why Fgfr1, with the hush puppy mutation, may not be capable of activating its signalling pathways: (1) the mutation may prevent interaction with FGF1, (2) once stimulated, the mutated receptor may be unable to dimerise and autophosphorylate, and (3) the mutated receptor may be unable to phosphorylate its target proteins. Due to the location of the mutation in the tyrosine kinase domain, it is most likely that either or both of the last two hypotheses account for the phenotype.

Tyrosine kinases have 11 conserved domains in their catalytic region, with the greatest degree of conservation occurring in subdomains VI-IX (Hanks et al. [@CR16]). The hush puppy mutation in *Fgfr1* occurs in the middle of subdomain IX, conserved in the majority of tyrosine kinase receptors, including all four isoforms of the Fgfr family, and for the Fgfr1 isoform it is conserved from zebrafish to human. In the hush puppy mutant, a tryptophan residue (a hydrophobic amino acid) located at the end of an alpha helix (Mohammadi et al. [@CR33]) is replaced by an arginine, a smaller hydrophilic residue, and is likely to cause disruption to the secondary structure of this region. Such a model had been proposed previously for a tyrosine kinase receptor, the insulin receptor, with a similar mutation. The tryptophan residue in the same location in subdomain IX in the insulin receptor (W1227, Supplementary Fig. 10; originally referred to as W1200S) was found to be mutated to serine in a heterozygous female patient with non-insulin-dependent diabetes mellitus, polycystic ovarian disease, and acanthosis nigricans (Grigorescu et al. [@CR11]; Moller and Flier [@CR34]). Insulin receptors with the W1227S mutation were noted to have a 70% impairment of receptor autophosphorylation when stimulated and were unable to catalyse tyrosyl phosphorylation of substrate proteins (Grigorescu et al. [@CR11]; Moller et al. [@CR35]). It was proposed that the mutation may destabilize the hydrophobic packing of the C-terminal lobe due to the inclusion of the hydrophilic substitute residue, in turn affecting the tyrosine kinase function (Hubbard et al. [@CR21]). As both the insulin receptor and *Fgfr1* mutations have similar hydrophilic substitutions at the same location, this destabilisation effect may also occur in Fgfr1 in the hush puppy mutant. In another example, dominantly inherited CATSHL syndrome (camptodactyly, tall stature, and hearing loss) is associated with a histidine-to-arginine missense mutation in the tyrosine kinase domain of FGFR3, although no defects of the middle ear were detected in affected individuals (Toydemir et al. [@CR53]).

The hush puppy mutation leads to dominant inheritance of pinna and ossicle malformations, skull anomalies, reduced rows of cochlear hair cells, and raised thresholds for auditory responses in heterozygous animals (Pau et al. [@CR39]). Previous reports of other Fgfr1 mutations have not mentioned dominant inheritance of any of these features (Deng et al. [@CR6]; Yamaguchi et al. [@CR59]), although other dominant effects such as a low penetrance of posterior vertebral transformations in heterozygotes for the Y766F mutation have been reported (Partanen et al. [@CR38]). Pinna and ossicle defects were reported in mice homozygous for hypomorphic mutations that reduced Fgfr1 levels to 10--20% (Partanen et al. [@CR38]), suggesting that the developing embryo is sensitive to receptor level. The hush puppy mutation may have a dominant effect by reducing in some way wild-type Fgfr1 protein to less than the predicted 50% of normal levels in heterozygotes, or the mutant protein may interact with wild-type protein in a way that reduces its activity. For example, if a mutant receptor dimerised with a wild-type receptor, it may inhibit activity of the wild-type Fgfr1 partner, reducing effective activity to the predicted 25% of dimers containing only wild-type receptor. Alternatively, mutant protein may influence the kinetics of the receptor and/or dimer. Other mutations in human *FGFR1* have previously been suggested to act in a dominant negative manner in Kallmann syndrome (Dode et al. [@CR7]; Pitteloud et al. [@CR43]).

The pinna and the middle ear ossicles are both derived from the same embryological origins, the pharyngeal arches (PA). The pinna develops from several hillocks that arise at the dorsal base of PA1 and PA2. The caudal region of PA1 gives rise to the malleus and the incus, as well as the mandible, while the stapes is derived from PA2 (for review see Mallo [@CR30]). Mutants expressing 10--20% of normal Fgfr1 levels have been shown to have greatly reduced pinna size at birth (Partanen et al. [@CR38]; Trokovic et al. [@CR54]), coupled with ossicle defects of varying severity, including absence of most ossicles (Trokovic et al. [@CR54]). The Fgfr1 hypomorph with 20% expression showed a reduction in size of PA2 from E9.5 due to a failure of migration of neural crest cells into the area (Trokovic et al. [@CR54]). It was proposed that Fgfr1 is involved in patterning of the pharyngeal region and plays a permissive role in the migration of neural crest cells into PA2.

A study by Hoch and Soriano ([@CR19]) also found defects in PA2 development related to Fgfr1 signalling. One of the proteins that Fgfr1 phosphorylates is fibroblast growth factor receptor substrate 2 (FRS2α and -β) (Kouhara et al. [@CR26]). FRS2 activates the Ras/MAP kinase pathway via two routes: (1) recruiting Grb2/Sos complexes, which activate the pathway (Hadari et al. [@CR13]; Kouhara et al. [@CR26]), and (2) binding the protein tyrosine phosphatase Shp2, which in turn activates Grb2 (Hadari et al. [@CR13], [@CR14]). Embryos with Fgfr1 that lacks the binding site for FRS2α die during late embryogenesis, with defects in neural tube closure and development of the tail bud (Hoch and Soriano [@CR19]). It was also found that there were defects in the development of the PAs such that PA2 was hypoplastic by E10.5 due to a large reduction in proliferation of the mesenchymal cells. The derivatives of PA2 were selectively affected in mutant embryos, with E15.5 embryos having missing or hypoplastic stapes. Combining the evidence described here, it would seem plausible that patterning defects in PA2 due to a reduction in Fgfr1 signalling cause the hush puppy heterozygous phenotype. The stapes defect could be the result of insufficient FRS2α activation due to a decrease in functional Fgfr1.

We propose that the missense mutation W691R in the *Fgfr1* gene is responsible for the phenotypic defects in hush puppy mice for several reasons. Firstly, the gene is located in the nonrecombinant region of chromosome 8 (Pau et al. [@CR39]), and the most penetrant feature (the stapes crura malformation) always segregates with the mutation. Secondly, *Fgfr1* is known to be expressed widely in the craniofacial region, including structures affected by the mutation (Bachler and Neubüser [@CR3]; Rice et al. [@CR45]). Thirdly, the affected residue is highly conserved and is located in an important functional region, the kinase domain. Fourthly, we have shown that the mutation affects two key roles of the receptor, its ability to activate the IP~3~ pathway and the RAS/MAP kinase pathway. Finally, the hush puppy mutant has several features in common with known hypomorphic mutations of *Fgfr1*, such as lethality of the homozygotes at around the time of gastrulation, malformation of the stapes, and pinna defects (Hoch and Soriano [@CR19]; Trokovic et al. [@CR54]).

We found some variation in the phenotype of hush puppy mutants, including asymmetric defects in individual mice. Variability in the phenotype has been reported for other mutations of *Fgfr1*, and mixed genetic background is known to be a complicating factor influencing penetrance of the abnormalities (Hoch and Soriano [@CR19]). The hush puppy mutation originated and is maintained on an inbred C3HeB/FeJ genetic background, indicating that the variability in phenotype most likely is influenced by stochastic events in addition to genetic background effects.

Modifier genes have been found for numerous pathological mutations, including those responsible for deafness, and range from genes affecting transcription or translation, such as *Nxf1*, an RNA export protein that can compensate for large intronic IAP insertions (Floyd et al. [@CR9]), to genes directly involved in the mechanisms affected by the mutation, in either the same pathway or possibly an alternative one such as the modifier of tubby hearing (*moth1*), which is an allele of the neuron-specific gene *Mtap1a* (Ikeda et al. [@CR22]). In the case of hush puppy, the mutation appears to disable the phosphorylation ability of the protein, so a modifier might be expected to compensate for that inability. The stapes and pinna genome scans indicate that a potential modifier (*Mhspy*) of these aspects of the hush puppy phenotype is located at the distal end of chromosome 7. Interestingly, this region includes *Fgfr2*, another tyrosine kinase receptor known to be expressed in the otic epithelium in a similar way to *Fgfr1* (Pirvola et al. [@CR41]). The four Fgf receptors have a conserved structure with varying degrees of homology in the different domains \[from 21--38% in the amino-terminal domain to 74--92% in the tyrosine kinase domain (Partanen et al. [@CR37])\] and can bind multiple FGF ligands (Givol and Yayon [@CR10]; Zhang et al. [@CR60]). Like *Fgfr1*, mutations in *Fgfr2* can lead to Pfeiffer syndrome (Schell et al. [@CR50]). In the process of lens differentiation, Fgfr1, Fgfr2, and Fgfr3 are functionally redundant (Zhao et al. [@CR61]), and in other situations, mutations in *Fgfr2* allow Fgfr2 to fulfill the role of Fgfr1 where it would otherwise be incapable; for example, Fgfr2 is not normally capable of Fgf1 translocation, but two amino acid changes in the C-terminus enable the protein to do that (Sørensen et al. [@CR51]). Other mutations in *Fgfr2* have been shown to increase signalling, particularly through affecting FRS (Ahmed et al. [@CR1]; Hatch et al. [@CR17]; Moffa and Ethier [@CR32]), so *Fgfr2* would be a prime candidate in a search for this modifier. Other genes encoding components of FGF signalling pathways are located on distal chromosome 7 and are also candidates for *Mhspy*, including *Fgf3*, *Fgf4*, and *Fgf15*. *Dusp8* on distal chromosome 7 may also be a candidate, because a related gene, *Dusp6*, has been shown to regulate Fgf signalling (Li et al. [@CR29]). Comparisons of coding and splice site sequence in these five potential modifier genes between the C57BL/6J reference sequence and C3H/HeJ (a related C3H line) show no obvious differences that might explain the modifier effect observed. However, there are several SNPs that are either synonymous or present in the UTRs of *Fgf3*, *Fgf4*, *Fgf15*, and *Dusp8*, and it is possible that these could play a role. We found suggestive evidence that *Mhspy* may be subject to imprinting, although none of these candidate genes has been reported to be imprinted. We compared the reported C57BL/6J and C3H/HeJ sequence for exons, splice sites, and UTRs of genes within or close to the known imprinted clusters on distal chromosome 7 (*H19*, *Igf2*, *Ins2* in one cluster and *Osbp15*, *Nap1l4*, *Phlda2*, *Tssc5/Slc22a18*, *Cdkn1c*, *Kcnq1*, *Kcnq1ot1*, *Tssc4*, *Cd81*, and *Ascl2* in the other cluster, plus *Cars* which is close to imprinted regions). *Cars* showed one nonsynonymous SNP at position 150745083 (rs13459436), changing a serine to glycine, but no other reliable sequence changes were observed.

Mutations in *Fgfr1* have been identified in several human syndromes. Pfeiffer syndrome is caused by a variety of mutations in *Fgfr1*, causing a range of symptoms such as premature skull fusion, underdevelopment of the midface, defects of the hands and feet, and deafness in \~50% of cases. However, it is unlikely that the hush puppy mutation is a model of Pfeiffer syndrome because the mutation in this human disease leads to upregulation of receptor function, whereas the hush puppy mutation in *Fgfr1* causes an inactive form of the receptor. Kallmann syndrome can be caused by loss-of-function mutations in FGFR1 (Albuisson et al. [@CR2]; Dode et al. [@CR7]; Pitteloud et al. [@CR42]; Sato et al. [@CR49]). This syndrome is characterised by hypogonadism and anosmia, but unilateral hearing loss has been reported in one individual (Dode et al. [@CR7]). Mice doubly heterozygous for the hush puppy mutation and a nonsense mutation in *Chd7* (another gene associated with Kallmann syndrome) show no sign of the Kallmann phenotype, so it would seem unlikely that hush puppy mice could be an animal model for Kallmann syndrome (Bergman et al. [@CR4]). A disease recently attributed to mutations in *Fgfr1* is osteoglophonic dysplasia, which is characterised by short stature, craniosynostosis, and bone demineralisation. This condition is caused by activating mutations of *Fgfr1* in specific extracellular and transmembrane regions of the gene (Supplementary Fig. 11) (White et al. [@CR57]). Although skull defects have been noted in hush puppy heterozygote animals, the hush puppy mutation is unlikely to be a model for this disorder due to the location of the mutation. However, as these examples show, it is only recently that human conditions are being attributed to mutations in *FGFR1*; therefore, the hush puppy *Fgfr1* mutant may yet be found to represent a human disorder (Supplementary Fig. 11) (Wilkie [@CR58]).
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Supplementary Fig. 1. Distribution of stapes by score (top; *n* = 366 stapes) and by sum of left and right scores (bottom; only animals with scores available for both ears were included. *N* = 168 animals. Mice with at least one ear with a solid stapes, score 8, were not included in this distribution; *n* = 4). All mice were backcross *Fgfr1*^*Hspy*^/+ heterozygotes. (TIFF 71 kb)
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Supplementary Fig. 2. Pinnae of backcross *Fgfr1*^*Hspy*^/+ mice. Pinna sizes range from quite normal pinna (A) to very small pinna (C). Black line indicates proximal border of measured pinna area. (TIFF 4924 kb)
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Supplementary Fig. 3. Distribution of pinna sizes in backcross *Fgfr1*^*Hspy*^/+ mice. **A**. Pinna distribution by size at 5-8 weeks. Each pinna for which there was a measurement was included in the analysis (*n* = 338 pinnae). Units are arbitrary ImageJ units. **B**. Pinna distribution by size at 7.5-8 months. Each pinna for each animal at 7.5-8 months was included in the analysis separately (*n* = 52 pinnae). Units are arbitrary ImageJ units. **C**. Pinna distribution by sum of both left and right ears at 5-8 weeks of age. The surface area of each pinna was measured, and the sum of both pinnae was used to find the distribution. *N* = 168 animals. **D**. Pinna distribution by sum at 7.5-8 months. The surface area of each pinna was measured and the sum of both pinnae was used to find the distribution. *N* = 25 animals. (TIFF 126 kb)
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Supplementary Fig. 4. Genome scans using the sum of the pinnae surface area for both ears at 5-8 weeks. **A**. Polymorphic microsatellite markers (Table 4) were used on the DNA of animals who had pinnae whose surface area sum was greater than 80. These are therefore the most normal mice from the backcross; *n* = 44 animals. **B**. Polymorphic microsatellite markers (Table 4) were used on the DNA of animals who had pinnae whose surface area sum was less than 60. These are therefore the most abnormal mice from the back cross. *n* = 36 animals. (TIFF 367 kb)

###### 

Supplementary Fig. 5. Regression analysis comparing pinna size to stapes score of the same ear. A significant negative correlation was observed for both left ear (r = -0.665, *n* = 181, *P* \< 2.2 × 10^−16^) and right ear (r = -0.617, *n* = 182, *P* \< 2.2 × 10^−16^). The left ear line has the formula Y = -2.91X + 46.49, and the right ear line Y = -2.65X + 46.32, where X is the stapes score and Y the pinna size. Left and right ears were treated separately to ensure independence; the similarity of the regression line formulae supports the significance of the effect. (TIFF 166 kb)
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Supplementary Fig. 6. Skulls of hush puppy heterozygotes from the backcross including examples of a skull that is quite normal (A) and one that is much shorter (B). Hushpuppy skulls also can have curved noses, to either side (C,D). (TIFF 3714 kb)
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Supplementary Fig. 7. Skull length and ratio distribution. **A**. Skull length distribution at age 5-8 weeks; *n* = 173 skulls. **B**. Skull length distribution at 7.5-8 months; *n* = 25 skulls. **C**. Distribution of skull length:width ratio; *n* = 198 skulls. (TIFF 99 kb)
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Supplementary Fig. 8. Genome scans using the ratio of skull length to skull width. **A**. Polymorphic microsatellite markers (Table 4) were used on the DNA of animals who had length:width ratios less than 2; *n* = 49 animals. **B**. Polymorphic microsatellite markers (Table 4) were used on the DNA of animals who had length:width ratios greater than 2.08. *n* = 49 skulls. (TIFF 191 kb)
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Supplementary Fig. 9. Genome scan using angle of the nose. **A**. Polymorphic microsatellite markers (Table 4) were used on the DNA of animals with straight noses (less than a 2 degree angle); *n* = 140. **B**. Polymorphic microsatellite markers (Table 4) were used on the DNA of animals with a nose angle greater than 10 degrees; *n* = 30. (TIFF 181 kb)
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Supplementary Fig. 10. Alignments of tyrosine kinase subdomain IX from the insulin receptor (INSR) and Fgfr1. The box encloses the residue that is mutated in a diabetic patients insulin receptor, and the hush puppy mutation in Fgfr1. Numbers shown are residue numbers for the boxed amino acid in each sequence. hINSR residue numbers are from accession number NP_000199. h = human; m = murine; A~2~ = patient number of subject with mutated insulin receptor (Grigorescu et al. 1986). (TIFF 330 kb)
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Supplementary Fig. 11. Mutations in *FGFR1* in human diseases. Diagram showing the structure of human and mouse Fgfr1, with known disease-causing mutations indicated along the sequence by vertical red lines (Wilkie 2008). The hush puppy mutation is indicated by a vertical violet line, and is flanked on both sides by mutations leading to various human syndromes. (TIFF 361 kb)
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